Second IRISCAT seminar
Vaccine mediated protection against SARS-CoV-2. Role of neutralizing antibodies
Dr Julià Blanco, IGTP Researcher since 1999 and leader of the Cell Virology and Immunology (VIC) group at The AIDS Research Institute, IrsiCaixa in Badalona (Barcelona) will led the webinar 'Vaccine mediated protection against SARS-CoV-2. Role of neutralizing antibodies'.
This huge impact of COVID-19 in global health has prompted an unprecedented research taskforce focused on the development of new vaccines able to generate protective immunity against the virus. To guide vaccine development, the understanding of the interplay between the virus and the immune system and therefore the identification of protective mechanisms have also been established as research priorities. Both aspects and the progress in vaccine development will be discussed.
Dr Julià Blanco is PhD in Biochemistry (University of Barcelona, 1994), during his post-doctoral training at Institut Pasteur in Paris, Dr Blanco studied the role of the HIV envelope glycoprotein (Env) in viral pathogenesis. Then he moved to its current position to develop research on HIV Env in a translational environment, analyzing the mechanisms involved in CD4 T-cell depletion in vivo and developing experimental models for the analysis of cell-to-cell HIV transmission and Env-induced cell death. The knowledge generated on HIV Env function prompted Dr. Blanco to approach HIV vaccine research by developing new immunogens based in HIV Env and a novel and highly immunogenic vaccine platform. Dr Blanco recently co-founded AlbaJuna Therapeutics SL a spin-off whose main activity is the development of synthetic antibodies against HIV. All this knowledge has been recently extended to other pathogens, including SARS-CoV-2.